What is Catamaran Bio?
Based in Cambridge, MA, Catamaran Bio is a biotechnology firm dedicated to developing innovative cell therapies aimed at treating cancer. The company's focus on novel therapeutic approaches positions it within a rapidly evolving field, seeking to address unmet medical needs through advanced biological engineering.
How much funding has Catamaran Bio raised?
Catamaran Bio has raised a total of $42M across 1 funding round:
Series A
$42M
Series A (2020): $42M with participation from Takeda Pharmaceuticals U.S.A., Inc., Lightstone Ventures, SV Life Sciences, Astellas Venture Management LLC, and Sofinnova Partners
Key Investors in Catamaran Bio
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact the company's collective future.
SV Life Sciences
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
Lightstone Ventures
Lightstone Ventures backs founders turning cutting edge science into new therapies and medical technologies. Its team partners closely with biotech and medtech leaders, providing capital, insight and connections to help transform promising lab ideas into treatments for patients.
What's next for Catamaran Bio?
The recent major strategic investment signifies a pivotal moment for Catamaran Bio, likely enabling the company to accelerate its research and development pipelines, expand its clinical trial capabilities, and further solidify its market position. This enterprise-level funding suggests confidence from investors in the company's long-term growth trajectory and its potential to bring transformative cancer treatments to patients.
See full Catamaran Bio company page
